Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
Active, not recruiting · NCT05776004 · Registry updated 2026-01-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia | Bacterial Infections and Mycoses, Infections, bacterial infectious disease, bacterial pneumonia, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder | Active, not recruiting | Phase 2 | 2026-01-28 | NCT05776004 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eagle Pharmaceuticals, Inc. | 2 |
90 results · Page 1 of 4
Research sites
Swipe the table sideways for more columns.